# Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer

> **NCT02644863** · PHASE2 · UNKNOWN · sponsor: **Shenzhen Hornetcorn Bio-technology Company, LTD** · enrollment: 60 (estimated)

## Conditions studied

- Esophageal Neoplasms
- Neoplasms
- Digestive System Neoplasms
- Esophageal Cancer

## Interventions

- **DRUG:** Paclitaxel
- **BIOLOGICAL:** DC-CIK
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02644863
- **Lead sponsor:** Shenzhen Hornetcorn Bio-technology Company, LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2018-12
- **Final completion:** 2019-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02644863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02644863, "Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02644863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*